好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Better Sleep Now Can Lead to Better Cognition Later
Aging, Dementia, and Behavioral Neurology
P6 - Poster Session 6 (5:00 PM-6:00 PM)
13-003
To evaluate whether an integrated score derived from sleep state electrocortical activity predicts future performance on neuropsychological (NP) tests.
Sleep state electrocortical activity, as measured using electroencephalograms (EEG), is linked with cognitive function and dementia risk. The rich information in overnight EEG can be condensed into integrated scores using machine learning. The Brain Health Score (BHS) was derived in prior work using an end-to-end deep learning model trained to jointly optimize higher cognitive function and lower disease risk from raw EEG, and correlates with NP test scores.

This study included 426 Framingham Heart Study (FHS) Generation 2 or Omni 1 participants with BHS values from in-home polysomnography in mid-to-late life, and subsequent digital clock drawing (dCDT) and NP testing an average of 12.6 years later. Linear regression models estimated associations between BHS and dCDT, memory, executive function, or language scores, adjusting for age, sex, race, education, smoking, body mass index, and FHS cohort. To enable comparison across outcomes, the independent variables were centered and rescaled, and then the model was refitted to generate standardized estimates. These standardized estimates were interpreted as the standard deviation (SD) change in each cognitive outcome associated with each 1-SD higher BHS. Higher BHS indicates better brain health (higher cognition and lower disease risk).
Participants were on average 56 years at sleep assessment, 55% female, and 86% non-Hispanic White. Each 1-SD higher BHS was associated with higher dCDT, memory, language, and executive function scores (dCDT: β: 0.16, 95% CI: 0.06-0.26; memory: β: 0.13, 95% CI: 0.03-0.23; language: β: 0.13, 95% CI: 0.03-0.23; executive: β: 0.10, 95% CI: 0.01-0.19).
Higher BHS in mid-to-late life was associated with better digital and traditional NP performance more than a decade later. These findings support the potential of EEG-derived, data-driven scores as a biomarker of future cognitive health.
Authors/Disclosures
Francesca Marino, PhD
PRESENTER 		The institution of Dr. Marino has received research support from National Institutes of Health.
Wolfgang Ganglberger, PhD Dr. Ganglberger has nothing to disclose.
Haoqi Sun, PhD (Massachusetts General Hospital) Dr. Sun has nothing to disclose.
Yulin Liu, Data manager Mrs. Liu has nothing to disclose.
Ding Ding, PhD Prof. Ding has nothing to disclose.
Robert J. Thomas, MD (Beth Israel Deaconess Medical Center) Dr. Thomas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG Councils. Dr. Thomas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global. Dr. Thomas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Thomas has received intellectual property interests from a discovery or technology relating to health care. Dr. Thomas has received publishing royalties from a publication relating to health care.
Rhoda Au, PhD (Boston University School of Medicine) Dr. Au has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NovoNordisk. Dr. Au has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GSK. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Au has received publishing royalties from a publication relating to health care. Dr. Au has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant with Davos Alzheimer's Collaborative. Dr. Au has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant with High Lantern.
M. B. Westover, MD, PhD (MGH) Dr. Westover has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Beacon Biosignals. Dr. Westover has stock in Beacon Biosignals. The institution of Dr. Westover has received research support from NIH. Dr. Westover has received publishing royalties from a publication relating to health care. Dr. Westover has a non-compensated relationship as a cofounder with Beacon Biosignals that is relevant to AAN interests or activities.